The suPAR biomarker predicts critical illness across diseases by measuring the level of activation in the immune response.
suPARnostic® is a reliable prognostic tool that enables healthcare professionals to make quick and informed patient triaging decisions at Emergency departments.
How to interpret suPAR results
suPAR level < 4 ng/ml
Supports patient discharge
suPAR level > 6 ng/ml
Supports patient hospitalisation
Lead with confidence
suPARnostic® empowers healthcare professionals to lead patient triage with confidence by making better-informed decisions backed by reliable biological data across diseases.
Implementing the biomarker suPAR in clinical care delivers faster and safer patient discharges, reduces re-admissions, unnecessary admissions, as well as hospital length-of-stay. – Freeing up critical resources, valuable time, and saving hospital beds for those who need them.
Improve patient care
Up to 22% reduction in hospital admissions and up to 6% reduction in hospital length-of-stay per patient
Reduce healthcare costs
Up to €100-380 savings per admission depending on medical specialty and geography
Empower clinical staff
Get more information to make more confident decisions to potentially reduce uncertainty and stress
“It has become clear that suPAR is a very strong prognostic marker, exceeding the prognostic value of all other routinely measured biomarkers in our hospital.”
Prof. Ove Andersen,
MD, PhD, DmSc, Copenhagen University Hospital Hvidovre, Denmark
suPAR News Vol. 3, June 2020
How suPARnostic® works at the Emergency Department
A patient is admitted to the ED for observation
The patient’s blood sample is drawn
The patient’s suPAR level is measured at the central lab
(~20 minutes) and fits existing hospital workflow.
The physician gets the result and makes a triage decision
suPAR is a significant independent predictor of mortality of ED patients
|n = 4,343||Patients dead after 30 days||Patients alive after 30 days||PPV/NPV|
|suPAR ≥6 ng/ml||133||509||PPV|
|suPAR >3 and l||77||1,580|
|suPAR ≤3 ng/ml||14||2,030||NPV|
(suPAR ≤3 versus
Source: Rasmussen LJH, Ladelund S, Haupt TH, et al. Emerg Med J 2016;33:769-775